-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Clinicians elderly patients in anti-neutrophil cytoplasmic antibodies (ANCA-) associated vascular poorly understood inflammation (the AAV)
Antineutrophil cytoplasmic antibody blood vessel
Recently, an authoritative journal in the field of internal medicine published a research article in the Journal of Internal Medicine.
The data of AAV patients ≥65 years of age come from the French Vasculitis Research Group (FVSG) database and the observation call for FVSG members
The analysis included 219 patients over 75 years old (median 79 years old) and 80 patients 65-75 years old (median 70 years old).
immunity
It can be seen that although the possibility of receiving a combination of glucocorticoid and immunosuppressant maintenance therapy is low, the risk of recurrence of AAV patients over 75 years old is lower than that of patients 65-75 years old, but they still benefit from this treatment option
Although the possibility of receiving a combination of glucocorticoid and immunosuppressant maintenance therapy is low, the risk of recurrence of AAV patients over 75 years is lower than that of patients 65-75 years old, but they still benefit from this treatment
Original source:
Sara Thietart,et al.
Patients of 75 years and over with ANCA -associated vasculitis have a lower relapse risk than younger patients: A multicentre cohort study
in this message
